dc.contributor.author | Özmen, Vahit | |
dc.contributor.author | Çakar, Burcu | |
dc.contributor.author | Gökmen, Erhan | |
dc.contributor.author | Özdoğan, Mustafa | |
dc.contributor.author | Güler, Nilufer | |
dc.contributor.author | Uras, Cihan | |
dc.contributor.author | Ok, Engin | |
dc.contributor.author | Demircan, Orhan | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Saip, Pınar | |
dc.date.accessioned | 2021-06-03T05:20:12Z | |
dc.date.available | 2021-06-03T05:20:12Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2587-0831 | |
dc.identifier.uri | http://dx.doi.org/10.5152/ejbh.2019.4761 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619785/ | |
dc.identifier.uri | http://hdl.handle.net/11655/24003 | |
dc.description.abstract | Objective Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective. Materials and Methods A Markov model was developed to make long term projections of distant recurrence, survival, quality adjusted life expectancy, and direct costs for patients with ER+, HER2-, node-negative or up to 3 node-positive early stage breast cancer. Turkish decision impact study patient data were captured for model reference. In that study, ten academic centers across Turkey participated in a prospective trial. Of 165 patients with pT1–3, pN0-N1mic, ER-positive, and HER-2 negative tumors, 57% had low recurrence score (RS), 35% had intermediate RS, and 8% had high RS, respectively. The overall rate of change in chemotherapy treatment decisions following Oncotype DX was 33%. Results The cost of adjuvant chemotherapy in public hospitals was estimated at $3.649, and Oncotype Dx test was $5.141. Based on the cost-effectiveness analysis, Oncotype DX testing was estimated to improve life expectancy (+0.86 years) and quality-adjusted life expectancy (+0.68 QALYs) versus standard care. The incremental cost-effectiveness ratio (ICERs) of Oncotype DX was estimated to be $7207.9 per QALY gained and $5720.6 per LY gained versus current clinical practice. Conclusion As Oncotype DX was found both cost-effective and life-saving from a national perspective, the test should be introduced to standard care in patients with ER+, HER-2 negative early-stage breast cancer in Turkey. | |
dc.language.iso | en | |
dc.relation.isversionof | 10.5152/ejbh.2019.4761 | |
dc.rights | Attribution 4.0 United States | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Cost Effectiveness Of Gene Expression Profiling In Patients With Early-Stage Breast Cancer In A Middle-Income Country, Turkey: Results Of A Prospective Multicenter Study | |
dc.title.alternative | Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | European Journal Of Breast Health | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 15 | |
dc.identifier.issue | 3 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |